For men with early, localized prostate cancer, immediate androgen suppression after radiotherapy significantly improves disease-free and overall survival. These tumors, however, can become resistant to androgen deprivation therapy over time.
In this ReCAP, Professor Johann de Bono of The Institute of Cancer Research, in London, discusses improvements in chemical castration and improved survival benefits from androgen receptor antagonist therapy in men with rising PSA levels. He also reports on updated trials looking at apalutamide, enzalutamide, and darolutamide, from ASCO 2020.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Nonmetastatic Castration-Resistant Prostate Cancer - Medscape - Jun 30, 2020.
Comments